Welcome. We are iOmx

iOmx is a clinical-stage biotech company that harnesses deep tumor immunology insights to generate novel treatments for the most prevalent solid tumor indications. The company is translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs.

iomx_we-are-iomx
On the cutting edge of Biotech

Advancing the Next Generation of Immuno-Oncology Therapies

Our Pipeline
Science with Purpose

Driven by Impact

Driving Impact Investors

Learn More

Your next big Career step.

Work at iOmx
a novel SIK inhibitor

OMX-0407

OMX-0407 is an orally available, first-in-class spectrum-selective inhibitor of SIK (salt-inducible kinase). The SIK family member SIK3 was identified as a novel immune checkpoint target in tumor cells by using iOmx’s systematic screening platform, iOTarg™. SIK3 is known for regulating the NF-κB-driven gene landscape through phosphorylation of class IIa histone deacetylases (HDACs) and CREB-regulated transcriptional coactivators causing the tumor to evade death receptor-mediated killing.

Lern more